Publication | Closed Access

An anti‐factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A

InflammationImmunohematologyThrombosisAllergyHematologyImmunologyHemostasisCoagulant PotentialsCoagulopathyImmunotherapyMedicineHealth Sciences